Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001374083 | SCV001570855 | likely benign | Gorlin syndrome; Medulloblastoma | 2024-01-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002447496 | SCV002682707 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-12-18 | criteria provided, single submitter | clinical testing | The c.882C>T variant (also known as p.G294G), located in coding exon 7 of the SUFU gene, results from a C to T substitution at nucleotide position 882. This nucleotide substitution does not change the at codon 294. However, this change occurs in the base pair of coding exon 7, which makes it likely to have some effect on normal mRNA splicing. This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will result in the creation or strengthening of a novel splice donor site. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV004762135 | SCV005368984 | uncertain significance | not provided | 2023-06-21 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; Has not been previously published as pathogenic or benign to our knowledge |